BioLineRx Balance Sheet - Quarterly (NASDAQ:BLRX)

Add to My Stocks
$0.98 $0.1 (9.26%) BLRX stock closing price Sep 21, 2018 (Closing)

The BioLineRx balance sheet is a snapshot of the company's financial health at a given point of time, whereas the other two financial statements are for a particular accounting period. Financial strength can be guaged by performing BioLineRx stock analysis and by analyzing the balance sheet. Quarterly results announcements include the release of all three financial statements, of which the balance sheet is one. BioLineRx had a long term debt of $- at the end of 2018 Q2. To understand the debt servicing capacity of the company, one needs to look at BioLineRx operating cash flow and BioLineRx revenue also. BioLineRx debt to equity ratio is .

View and download BioLineRx quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Marketable Securities35.33M36.38M44.37M48.29M45.61M28.16M33.15M34.89M37.94M40.42M
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.23M---------
Total Current Assets
Property Plant & Equipment--4.35M---4.01M---
Accumulated Depreciation--1.84M---1.4M---
Net Property Plant & Equipment
Investment & Advances-1M1M1M------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable5.24M6.08M6.62M5.43M5.32M5.08M3.56M3.27M2.71M2.46M
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses----------
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities--1.2M1.39M------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net2.92M2.87M2.83M2.8M2.57M1.64M1.51M1.46M1.45M1.45M
Capital Surplus243.88M242.17M240.68M239.6M231.36M205.89M199.56M198.38M197.85M197.79M
Retained Earnings-210.54M-205.75M-199.55M-192.2M-184.95M-180.06M-175.2M-170.92M-166.58M-162.85M
Treasury Stock----------
Other Liabilities9.92M9.72M8.92M8.81M8.45M8.24M9.15M9.69M9.83M9.6M
Shareholders Equity46.18M49.02M52.88M59.02M57.43M35.71M35.02M38.6M42.56M46M
Total Liabilities & Shareholders Equity52.21M56.07M60.96M66.12M63.04M41.11M38.93M42.27M45.68M48.94M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the BioLineRx stock price, and BioLineRx historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the BioLineRx PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: BLRX total assets, which was at $52.21M for 2018 Q2 is a balance sheet item representing value of what BioLineRx owns. Assets are brought to aid a firms operations, or to increase its economic value. It must be noted that tech stocks may not have a lot of assets, as the value for these companies is often derived from future earning potential.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. BLRX stock had total liabilities of $6.02M for the quarter 2018 Q2.

BioLineRx Balance Sheet - Key Ratios